Pfizer Drug Death: Patient Dies After US Approval
- This article reports on the death of a patient participating in a clinical trial for a Pfizer drug, "Himbafzi," used to prevent or reduce bleeding episodes in patients...
- * Patient Death: A patient died on December 14th after experiencing a stroke followed by a brain hemorrhage.
- The article provides links to related keywords like Pfizer, the United States, brain hemorrhage, and hemophilia.
Summary of the article:
This article reports on the death of a patient participating in a clinical trial for a Pfizer drug, “Himbafzi,” used to prevent or reduce bleeding episodes in patients with hemophilia A or B.
Key points:
* Patient Death: A patient died on December 14th after experiencing a stroke followed by a brain hemorrhage.
* Drug Trial: The patient was enrolled in a study testing Himbafzi, a weekly injection targeting blood clotting proteins.
* Pfizer Response: Pfizer is actively investigating the incident with the relevant authorities and an independent data monitoring committee. They currently believe the death won’t impact the safety of patients already treated with the drug.
* Previous Approval: The drug received approval in the United States last year for specific hemophilia patients.
* Patient Group Report: The European Hemophilia Consortium reported the death.
The article provides links to related keywords like Pfizer, the United States, brain hemorrhage, and hemophilia.